QC6352 is an effective KDM4C inhibitor (IC50: 35±8 nM). QC6352 blocks the proliferation and self-renewal of BCSCs. In a concentration-dependent manner QC6352 dramatically decreases the anchorage-independent sphere-forming capacity of BCSC1 and BCSC2. The protein levels of (Epidermal growth factor receptor) EGFR are reduced in both BCSC1 and BCSC2 upon treatment with QC6352 [1][2].

QC6352 strongly affects tumor growth and the final tumor weight of both BCSC1 and BCSC2 xenografts. QC6352 treatment is well tolerated and does not affect body weight of the mice. Treatment with the KDM4 inhibitor QC6352 blocks BCSC xenograft tumor growth[2].